<DOC>
	<DOCNO>NCT01615874</DOCNO>
	<brief_summary>The purpose study assess effect one five possible study medication use treatment asthma blood plasma cortisol level child age 5-11 year persistent asthma .</brief_summary>
	<brief_title>Study Effect Mometasone Furoate/Formoterol ( MF/F ) , Montelukast Beclomethasone Dipropionate ( BDP ) Plasma Cortisol Levels Children 5-11 Years Old With Persistent Asthma ( P05574 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Mometasone Furoate , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>diagnosis persistent asthma ≥6 month duration body weight ≥18 kg able discontinue prescribe inhaled corticosteroid ( ICS ) ICS combine longacting betaagonist ( LABA ) start study medication use low medium daily dose ICS ( either alone combination LABA ) use oral corticosteroid within 3 month prior Screening Visit stable asthma regimen ( daily dose unchanged ) ≥2 week prior Screening Visit document positive responsiveness bronchodilator ability use peak flow meter correctly perform spirometry PEF measurement ability use inhaler correctly consent/assent trial pharmacogenetic testing ( Note : If unwilling consent/assent pharmacogenetic testing , inclusion study still allow , pharmacogenetic sample obtain . ) use high dose ICS ≥30 day within 6 month prior Screening Visit treatment emergency room ( severe asthma exacerbation require systemic corticosteroid treatment ) hospitalization management airway obstruction within 3 month prior Screening Visit ever require ventilator support respiratory failure secondary asthma upper low respiratory tract infection ( viral bacterial ) within 2 week prior Screening Visit clinically significant abnormal vital sign evidence oropharyngeal candidiasis history clinically significant renal , hepatic , cardiovascular , metabolic , neurologic , hematologic , ophthalmologic , respiratory , gastrointestinal , cerebrovascular , significant medical illness disorder may interfere study participation . Specific example include limited insulindependent diabetes , active hepatitis , cardiovascular disease include hypertension , condition may interfere respiratory function , bronchiectasis , cystic fibrosis allergy intolerance corticoid , beta2 agonist , montelukast inactive ingredient medication use study participation study another study site previous randomization study participation another investigational study duration study use investigational drug within one month prior Screening Visit previous participation study MF/F montelukast direct association family member one investigator study staff sibling participant study</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>